Spero Therapeutics, Inc. SPRO

Company Overview

Spero Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing treatments for bacterial infections and rare diseases with significant unmet medical need. The company operates within the biotechnology and pharmaceutical industries, with a primary emphasis on anti-infective therapeutics targeting multidrug-resistant bacterial pathogens. Its core business activities center on discovering, developing, and advancing novel therapeutic candidates through clinical development, licensing arrangements, and strategic collaborations.

The company’s primary value driver has been its development pipeline, particularly tebipenem HBr, an oral carbapenem antibiotic candidate for complicated urinary tract infections (cUTIs), including pyelonephritis. Spero has also advanced programs focused on rare infectious diseases and antimicrobial resistance. The company was founded in 2013 and evolved through acquisitions, licensing agreements, and internal research initiatives aimed at addressing gaps in antibiotic innovation. Its positioning has historically emphasized expertise in infectious disease therapeutics, oral antibiotic development, and partnerships with larger pharmaceutical organizations to support commercialization and late-stage development activities.